Thanks! You've successfully subscribed to the BONEZONE®/OMTEC® Monthly eNewsletter!

Please take a moment to tell us more about yourself and help us keep unwanted emails out of your inbox.

Choose one or more mailing lists:
BONEZONE/OMTEC Monthly eNewsletter
OMTEC Conference Updates
Advertising/Sponsorship Opportunities
Exhibiting Opportunities
* Indicates a required field.

206 Ortho Secures Patent for Technology That Incorporates Biodegradable Material

Small and growing companies continue to drive innovation in the orthopaedic industry. We recently wrote about some of them in our 1H18 patent activity recap.

Another company to add to this list is 206 Ortho, out of Lowell, Massachusetts. The company received its second patent covering a new bio-inspired composite and implants that could fix broken bones without the need for implant removal surgery. This high-strength biodegradable material is made of fibers comprising minerals naturally found in the body and bound by a biodegradable polymer. It is intended to repair load-bearing bone and resorb completely, and is already in use in orthopaedic implants and sutures. 

“This patented technology adds to our existing and growing portfolio of patented biomaterials and implants capable of changing the way orthopedic injury will be treated and managed," said Jeff D’Agostino, Founder and CEO of 206 Ortho.

206 Ortho—which has over 25 patent and patent applications—is pursuing additional funding and potential commercialization partners.

Metal implants have been used for over 100 years to provide stability for fractured bones during healing. According to information provided by 206 Ortho in its release announcing this new patent, roughly four out of five orthopaedic patients live with pain and discomfort and approximately 40% undergo surgery to remove the metal implant due to the pain. These implant removal surgeries add billions of dollars to the cost of healthcare, as well as additional patient trauma.

“We are confident that …this newly issued patent will impact the effectiveness and costs associated with orthopaedic surgery,” D’Agostino said. “This is particularly important as our global healthcare system evolves to a value-based patient care model."

D’Agostino, a veteran of over 19 years in the medical device and pharmaceutical industries, founded 206 Ortho in 2011. The company’s list of advisors includes Richard Randall, former CEO of OMNIlife Science.

Rob Meyer is ORTHOWORLD’s Senior Editor. Please send comments on this article to This email address is being protected from spambots. You need JavaScript enabled to view it..

ORTHOWORLD’s Editorial Assistant Julie A. Vetalice contributed to this report. She can be reached by email.